Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Immuneering Corp

Get SEC filing alerts via email and in your feed for Immuneering Corp

IMRX

Immuneering Corp

About Immuneering Corp

Immuneering Corporation is a biotech company focused on developing targeted cancer therapies using proprietary bioinformatics and translational models. Its pipeline includes oral small molecule inhibitors like IMM-1-104 and IMM-6-415, designed to disrupt MAPK pathway signaling with improved tolerability and resistance profiles. The company targets solid tumors driven by RAS/RAF mutations, leveraging innovative cyclic inhibition mechanisms to enhance efficacy and safety in oncology markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Immuneering Corp

1
1
Immuneering Corp Immuneering Reports $13.5 Million Net Loss in Q1 2026, Decreased from Previous Year

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
Immuneering Corp Immuneering Corporation Reports $56M Net Loss and Operational Updates in 10-K Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Immuneering Corp Immuneering Reports Q3 2025 Financial Results with Increased Net Loss and Significant Cash Reserves

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Immuneering Corp Immuneering Reports $29.5 Million Net Loss for First Half of 2025, Focuses on Clinical Trials

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Immuneering Corp Immuneering Reports $15M Net Loss in Q1 2025, Faces Ongoing Financial Challenges

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Immuneering Corp Immuneering Corp. Reports $61M Net Loss for 2024, Highlights Clinical Trial Developments

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Immuneering Corp Immuneering Corporation Reports Net Loss and Decreased Cash Reserves in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments